Liquid Biopsy and Pancreas Cancer: Detection of AXL(+) CTCs (CTC-AXL-PANC)

NARecruitingINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

June 16, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 1, 2027

Conditions
Pancreatic Ductal AdenocarcinomaMetastatic Pancreatic CancerCirculating Tumor Cell
Interventions
OTHER

Detection of circulating tumor cells expressing Axl: CTC-AXL(+)

"Detection of CTC-AXL(+) using 2 techniques:~* CellSearch®, FDA-USA approved technology~* EPIDROP System~CellSearch® (Menarini Company) The current gold-standard CellSearch® technique requires the use of CellSave tubes. This technique allows the isolation of fixed CTCs. This technique uses a positive (CellSearch® Epithelial Cell Kit) enrichment method from total blood using magnetic beads coupled to an EpCAM capture antibody. CTCs are then detected (anti-panCK antibodies, DAPI, anti-CD45 and characterized (anti-AXL antibody) by immunofluorescence (IF).~EPIDROP It requires the use of EDTA tubes. This technique is based on a method of negative enrichment of CTCs from total blood using a cocktail of tetrameric antibodies to eliminate unwanted blood cells and to preserve only purified tumor cells (RosetteSep - StemCell Technology).Then, cells are loaded in a microfluidic chip. The detection and characterization is done by IF to the single cell in micro-droplets."

Trial Locations (1)

34090

RECRUITING

CHU Montpellier, Montpellier

All Listed Sponsors
lead

University Hospital, Montpellier

OTHER